WO2015159239A4 - A method for diagnosing tuberculous meningitis - Google Patents
A method for diagnosing tuberculous meningitis Download PDFInfo
- Publication number
- WO2015159239A4 WO2015159239A4 PCT/IB2015/052751 IB2015052751W WO2015159239A4 WO 2015159239 A4 WO2015159239 A4 WO 2015159239A4 IB 2015052751 W IB2015052751 W IB 2015052751W WO 2015159239 A4 WO2015159239 A4 WO 2015159239A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tbm
- sample
- biomarkers
- capture agents
- levels
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
A method for diagnosing tuberculous meningitis (TBM) is described herein. A fluid sample from a subject suspected of having TBM is tested for the presence of at least two of Interleukin-13 (IL-13), Vascular endothelial growth factor (VEGF), Cathelicidin (LL-37), IL- 7, IL-12p70, IFN-γ, IL-6, IL-10, IL-13, IP-10, MIP-1a, MIP-1b, RANTES and GM-CSF. Increased levels of at least any two of these biomarkers in the sample compared to levels in subjects without TBM are indicative that the subject has TBM.
Claims
1 . A method of diagnosing tuberculous meningitis (TBM), the method comprising the steps of:
measuring the levels of at least lnterleukin-13 (IL-13), Vascular endothelial growth factor (VEGF) and Cathelicidin (LL-37) in a sample from a subject suspected of having TBM; and
determining whether the subject has TBM based on the levels of the biomarkers in the sample.
2. A method according to claim 1 , wherein a positive diagnosis for TBM is made when the level of IL-13, VEGF and/or LL-37 in the sample is higher than a typical level of the same biomarker in subjects without tuberculous meningitis.
3. A method according to either of claims 1 or 2, which further comprises measuring the levels of one or more of the following additional biomarkers: IL-17, IL-12p70, IFN-γ, IL- 6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b, RANTES and GM-CSF.
4. A method according to any one of claims 1 to 3, wherein the sample is cerebrospinal fluid.
5. A method according to any one of claims 1 to 3, wherein the sample is serum.
6. A method according to any one of claims 1 to 5, wherein capture agents are used to bind each of the biomarkers.
7. A method according to claim 6, wherein the capture agents are selected from the group consisting of antibodies, affybodies, ankyrin repeat proteins, armadillo repeat proteins, nucleic acid aptamers, modified nucleic acid aptamers, peptides, modified peptides, carbohydrate ligands, synthetic ligands and synthetic polymers.
8. A method according to either of claims 6 or 7, wherein one or more indicators are provided to indicate when binding of each of the capture agents and biomarkers occurs.
9. A method according to claim 8, wherein the indicator is selected from the group consisting of a calorimetric, electrochemical, chromogenic, optical, fluorescent and a radio-labeled indicator.
10. A device for diagnosing tuberculous meningitis (TBM), the device comprising:
a means for receiving a sample from a subject suspected of having TBM;
capture agents for binding at least lnterleukin-13 (IL-13), Vascular endothelial growth factor (VEGF) and Cathelicidin (LL-37) if present in the sample; and
at least one indicator which indicates when the capture agents bind to the biomarkers.
1 1 . A device according to claim 10, wherein the capture agents are selected from the group consisting of antibodies, affybodies, ankyrin repeat proteins, armadillo repeat proteins, nucleic acid aptamers, modified nucleic acid aptamers, peptides, modified peptides, carbohydrate ligands, synthetic ligands and synthetic polymers.
12. A device according to either of claims 10 or 1 1 , wherein the indicator indicates binding of the capture agent to the biomarker by electrical, acoustic, optical or mechanical methods.
13. A device according to any one of claims 10 to 12, which includes measuring means for measuring the levels of the detected biomarkers.
14. A device according to any one of claims 10 to 13, which further includes amplifying means for increasing the sensitivity of the detection of the biomarkers.
15. A device according to any one of claims 10 to 15, which is a hand-held point-of-care device.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15779954.5A EP3132270A4 (en) | 2014-04-15 | 2015-04-15 | A method for diagnosing tuberculous meningitis |
| RU2016144359A RU2016144359A (en) | 2014-04-15 | 2015-04-15 | METHOD FOR DIAGNOSTIC OF TUBERCULOSIS Meningitis |
| AP2016009538A AP2016009538A0 (en) | 2014-04-15 | 2015-04-15 | A method for diagnosing tuberculous meningitis |
| CN201580019921.5A CN106461674A (en) | 2014-04-15 | 2015-04-15 | A method for diagnosing tuberculous meningitis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2014/02743 | 2014-04-15 | ||
| ZA201402743 | 2014-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015159239A1 WO2015159239A1 (en) | 2015-10-22 |
| WO2015159239A4 true WO2015159239A4 (en) | 2015-12-17 |
Family
ID=54323552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/052751 WO2015159239A1 (en) | 2014-04-15 | 2015-04-15 | A method for diagnosing tuberculous meningitis |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3132270A4 (en) |
| CN (1) | CN106461674A (en) |
| AP (1) | AP2016009538A0 (en) |
| RU (1) | RU2016144359A (en) |
| WO (1) | WO2015159239A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017178826A1 (en) * | 2016-04-14 | 2017-10-19 | The University Of Liverpool | Diagnosing acute bacterial meningitis |
| CN107421875A (en) * | 2017-04-29 | 2017-12-01 | 济南市儿童医院 | Mfsd2a is preparing the application in diagnosing purulent meningitis product |
| WO2019224755A1 (en) * | 2018-05-23 | 2019-11-28 | Stellenbosch University | Biomarkers for diagnosing tuberculous meningitis |
| CN112899340B (en) * | 2021-03-15 | 2022-09-27 | 首都医科大学附属北京胸科医院 | Reagent for assisting diagnosis of tubercular meningitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002095411A1 (en) * | 2001-05-18 | 2002-11-28 | Virogates Aps | A method of diagnosing or prognosticating major respiratory bacterial pathogens in a subject |
| NZ553386A (en) * | 2004-07-23 | 2010-05-28 | Aspenbio Pharma Inc | Methods and devices for diagnosis of appendicitis |
| US20110129817A1 (en) * | 2009-11-30 | 2011-06-02 | Baylor Research Institute | Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection |
| MX2010014556A (en) * | 2008-06-25 | 2011-07-28 | Baylor Res Inst | Blood transcriptional signature of mycobacterium tuberculosis infection. |
| WO2013175459A2 (en) * | 2012-05-25 | 2013-11-28 | Stellenbosch University | Method for diagnosing tuberculosis disease |
-
2015
- 2015-04-15 CN CN201580019921.5A patent/CN106461674A/en active Pending
- 2015-04-15 WO PCT/IB2015/052751 patent/WO2015159239A1/en active Application Filing
- 2015-04-15 RU RU2016144359A patent/RU2016144359A/en unknown
- 2015-04-15 EP EP15779954.5A patent/EP3132270A4/en not_active Withdrawn
- 2015-04-15 AP AP2016009538A patent/AP2016009538A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016144359A3 (en) | 2018-05-15 |
| CN106461674A (en) | 2017-02-22 |
| WO2015159239A1 (en) | 2015-10-22 |
| AP2016009538A0 (en) | 2016-11-30 |
| RU2016144359A (en) | 2018-05-15 |
| EP3132270A4 (en) | 2017-09-13 |
| EP3132270A1 (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530875A5 (en) | ||
| Leligdowicz et al. | Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection | |
| RU2016137685A (en) | DIAGNOSTIC METHOD OF TUBERCULOSIS | |
| WO2015159239A4 (en) | A method for diagnosing tuberculous meningitis | |
| Pieri et al. | KFLC Index utility in multiple sclerosis diagnosis: Further confirmation | |
| Oh et al. | Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma | |
| EP2791679A1 (en) | Methods and kits for diagnosing latent tuberculosis infection | |
| RU2017115663A (en) | METHODS AND SYSTEMS FOR DIFFERENTIATION OF AN IRRITATED INTESTINAL SYNDROME FROM AN INFLAMMATORY DISEASE OF THE INTESTINAL AND GLUTEN DISEASE | |
| WO2016161088A3 (en) | Biosensor system for the rapid detection of analytes | |
| JP2017502253A5 (en) | ||
| RU2016116766A (en) | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease | |
| JP2017531801A5 (en) | ||
| RU2013118307A (en) | A NEW METHOD FOR DIAGNOSTIC OF LYME DISEASE USING A CELL IMMUNE RESPONSE TEST | |
| Bayart et al. | Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute? | |
| Daly et al. | Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements | |
| JP2016521850A (en) | How to support differential diagnosis of stroke | |
| WO2012139052A3 (en) | Antibody biomarkers for diabetes | |
| JP2017524933A5 (en) | ||
| CN102866256B (en) | Detection method and detection reagent for hypersensitive C reactive protein | |
| WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
| JP2020526745A5 (en) | ||
| JP2014224759A5 (en) | ||
| CN105353135A (en) | Use of Alzheimer's disease marker | |
| Limberg et al. | Neurofilament light chain determination from peripheral blood samples | |
| Zhang et al. | Platelet proteomics in diagnostic differentiation of primary immune thrombocytopenia using SELDI-TOF-MS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15779954 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015779954 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2015779954 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2016144359 Country of ref document: RU Kind code of ref document: A |